These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 27916892)
1. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. Herrero AB; Rojas EA; Misiewicz-Krzeminska I; Krzeminski P; Gutiérrez NC Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916892 [TBL] [Abstract][Full Text] [Related]
2. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Wasylishen AR; Lozano G Cold Spring Harb Perspect Med; 2016 Aug; 6(8):. PubMed ID: 27329033 [TBL] [Abstract][Full Text] [Related]
3. A clinical, pathologic, and molecular study of p53 and murine double minute 2 in penile carcinogenesis and its relation to prognosis. Rocha RM; Ignácio JA; Jordán J; Carraro DM; Lisboa B; Lopes A; Carvalho KC; da Cunha IW; Cubilla A; Guimarães GC; Vassallo J; Soares FA Hum Pathol; 2012 Apr; 43(4):481-8. PubMed ID: 21925707 [TBL] [Abstract][Full Text] [Related]
4. MDM2-p53 pathway in hepatocellular carcinoma. Meng X; Franklin DA; Dong J; Zhang Y Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334 [TBL] [Abstract][Full Text] [Related]
5. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer. Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242 [TBL] [Abstract][Full Text] [Related]
6. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272 [TBL] [Abstract][Full Text] [Related]
7. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable. Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588 [TBL] [Abstract][Full Text] [Related]
8. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Toledo F; Wahl GM Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209 [TBL] [Abstract][Full Text] [Related]
9. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Toledo F; Wahl GM Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002 [TBL] [Abstract][Full Text] [Related]
10. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. Leventaki V; Rodic V; Tripp SR; Bayerl MG; Perkins SL; Barnette P; Schiffman JD; Miles RR Br J Haematol; 2012 Sep; 158(6):763-71. PubMed ID: 22845047 [TBL] [Abstract][Full Text] [Related]
11. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005 [TBL] [Abstract][Full Text] [Related]